Chaan S. Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chaan S. Ng has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
Wei Wei
Lerner Research Institute
15 shared publicationsAdam G. Chandler
Global Scientific Collaborations, United Imaging
12 shared publicationsChusilp Charnsangavej
Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
9 shared publicationsDelise H. Herron
Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
9 shared publicationsElla F. Anderson
Department of Radiology, Unit 1473, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
9 shared publicationsBrian P. Hobbs
Telperian, Inc
7 shared publications
Latest Publications
- 21 July 2026
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Computer Assisted Tomography
Effects of Antiangiogenic Agents on CT Perfusion Parameters in Liver Metastases From Renal Cell Carcinoma and Normal Liver
Objective: To investigate the effects of targeted antiangiogenic agents on CT perfusion parameter values in liver metastases from renal cell carcinoma (mRCC) and on normal liver, before and after initiation of therapy. Methods: CT perfusion parameter values of liver metastases from RCC and adjacent normal liver were evaluated before and after 8 weeks of bevacizumab and pazopanib. Perfusion parameters blood flow (BF), blood volume (BV), mean transit time (MTT), permeability surface area product (PS), portal venous perfusion (PVP), hepatic arterial perfusion (HAP), and hepatic arterial fraction (HAF) were derived from General Electric CT Perfusion (4D) software. Differences between tissues at baseline and percent changes (Ī) in perfusion values after therapy were evaluated by the Wilcoxon signed-rank test. Results: There were 9 patients in the study (6 bevacizumab, 3 pazopanib). BF, HAP, and HAF were significantly higher, and MTT significantly lower, in untreated metastases than normal liver (all P P =0.058). For the liver metastases 8 weeks after therapy, there were significant reductions in ĪBF, ĪBV, ĪHAP and ĪHAF compared with baseline: ā27.4% ( P =0.05), ā54.9% ( P =0.008), ā80.6% ( P =0.004), and ā46.6% ( P =0.019), respectively. No significant changes after 8 weeks of therapy were observed in normal liver for any of the 7 perfusion parameters. Conclusion: This small preliminary data set suggests that targeted antiangiogenic agents might have significant effects on tumor perfusion, which can be detected by CT perfusion just 8 weeks after initiation of therapy. The agents have differential effects on tumor and normal liver. CT perfusion may assist in monitoring therapies and offer insights into pathophysiological aspects of tumors.
- 21 July 2026
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Computer Assisted Tomography
Effects of Antiangiogenic Agents on CT Perfusion Parameters in Liver Metastases From Renal Cell Carcinoma and Normal Liver
Objective: To investigate the effects of targeted antiangiogenic agents on CT perfusion parameter values in liver metastases from renal cell carcinoma (mRCC) and on normal liver, before and after initiation of therapy. Methods: CT perfusion parameter values of liver metastases from RCC and adjacent normal liver were evaluated before and after 8 weeks of bevacizumab and pazopanib. Perfusion parameters blood flow (BF), blood volume (BV), mean transit time (MTT), permeability surface area product (PS), portal venous perfusion (PVP), hepatic arterial perfusion (HAP), and hepatic arterial fraction (HAF) were derived from General Electric CT Perfusion (4D) software. Differences between tissues at baseline and percent changes (Ī) in perfusion values after therapy were evaluated by the Wilcoxon signed-rank test. Results: There were 9 patients in the study (6 bevacizumab, 3 pazopanib). BF, HAP, and HAF were significantly higher, and MTT significantly lower, in untreated metastases than normal liver (all P P =0.058). For the liver metastases 8 weeks after therapy, there were significant reductions in ĪBF, ĪBV, ĪHAP and ĪHAF compared with baseline: ā27.4% ( P =0.05), ā54.9% ( P =0.008), ā80.6% ( P =0.004), and ā46.6% ( P =0.019), respectively. No significant changes after 8 weeks of therapy were observed in normal liver for any of the 7 perfusion parameters. Conclusion: This small preliminary data set suggests that targeted antiangiogenic agents might have significant effects on tumor perfusion, which can be detected by CT perfusion just 8 weeks after initiation of therapy. The agents have differential effects on tumor and normal liver. CT perfusion may assist in monitoring therapies and offer insights into pathophysiological aspects of tumors.
- Open Access
- 17 June 2026
- Published byĀ SAGE PublicationsĀ inĀ Technology in Cancer Research & Treatment
- Vol.Ā 25
CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma
Introduction: There is currently no biomarker for progression-free survival (PFS) for patients undergoing treatment for metastatic renal cell carcinoma (RCC). The aim of our study was to evaluate computed tomography perfusion (CTp) blood flow as an early marker of PFS in patients with mRCC treated with targeted agents. Methods: Associations between CTp blood flow and PFS were evaluated from prospective randomized evidence using univariable and multivariable Cox proportional hazards regression models with Harrellās concordance index (c-index) in patients with mRCC randomized to receive one of three targeted agents (everolimus, bevacizumab, or pazopanib). Analyses included baseline tumor CTp blood flow (BF 0 ) and changes in blood flow after 8 weeks of therapy (ĪBF). Demographic and clinical prognostic factors (International mRCC Database Consortium [IMDC] risk score and ECOG performance) were included in the models as covariates. Results: The median PFS of the 55-patient cohort was 0.80 years (95% CI: 0.76-1.38 years), with no significant difference among the targeted agents. ĪBF and BF 0 were significantly associated with PFS on univariable analysis (p=0.002 and p=0.013, respectively). Multivariable analyses incorporating all the above factors indicated that higher baseline BF 0 (>166 mL/min/100g) and reduced ĪBF (0 ) delineates tumors responsive to targeted therapy, while reductions in perfusion (ĪBF) just 8 weeks after starting treatment are associated with longer PFS. These findings arise from randomized evidence, warranting further evaluations.
- 17 June 2026
- Published byĀ SAGE PublicationsĀ inĀ Technology in Cancer Research & Treatment
- Vol.Ā 25
Open AccessCT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma
Introduction: There is currently no biomarker for progression-free survival (PFS) for patients undergoing treatment for metastatic renal cell carcinoma (RCC). The aim of our study was to evaluate computed tomography perfusion (CTp) blood flow as an early marker of PFS in patients with mRCC treated with targeted agents. Methods: Associations between CTp blood flow and PFS were evaluated from prospective randomized evidence using univariable and multivariable Cox proportional hazards regression models with Harrellās concordance index (c-index) in patients with mRCC randomized to receive one of three targeted agents (everolimus, bevacizumab, or pazopanib). Analyses included baseline tumor CTp blood flow (BF 0 ) and changes in blood flow after 8 weeks of therapy (ĪBF). Demographic and clinical prognostic factors (International mRCC Database Consortium [IMDC] risk score and ECOG performance) were included in the models as covariates. Results: The median PFS of the 55-patient cohort was 0.80 years (95% CI: 0.76-1.38 years), with no significant difference among the targeted agents. ĪBF and BF 0 were significantly associated with PFS on univariable analysis (p=0.002 and p=0.013, respectively). Multivariable analyses incorporating all the above factors indicated that higher baseline BF 0 (>166 mL/min/100g) and reduced ĪBF (0 ) delineates tumors responsive to targeted therapy, while reductions in perfusion (ĪBF) just 8 weeks after starting treatment are associated with longer PFS. These findings arise from randomized evidence, warranting further evaluations.
- Open Access
- 10 April 2023
- Published byĀ ElsevierĀ inĀ Research in Diagnostic and Interventional Imaging
- Vol.Ā 6, 100028
Effect of scan duration on CT perfusion values in metastases from renal cell carcinoma
- 10 April 2023
- Published byĀ ElsevierĀ inĀ Research in Diagnostic and Interventional Imaging
- Vol.Ā 6, 100028
Open AccessEffect of scan duration on CT perfusion values in metastases from renal cell carcinoma
- Open Access
- 23 September 2020
- Published byĀ Public Library of Science (PLoS)Ā inĀ PLOS ONE
- Vol.Ā 15 Ā (9) , e0238582
Comparison of virtual to true unenhanced abdominal computed tomography images acquired using rapid kV-switching dual energy imaging
To compare āvirtualā unenhanced (VUE) computed tomography (CT) images, reconstructed from rapid kVp-switching dual-energy computed tomography (DECT), to ātrueā unenhanced CT images (TUE), in clinical abdominal imaging. The ability to replace TUE with VUE images would have many clinical and operational advantages. VUE and TUE images of 60 DECT datasets acquired for standard-of-care CT of pancreatic cancer were retrospectively reviewed and compared, both quantitatively and qualitatively. Comparisons included quantitative evaluation of CT numbers (Hounsfield Units, HU) measured in 8 different tissues, and 6 qualitative image characteristics relevant to abdominal imaging, rated by 3 experienced radiologists. The observed quantitative and qualitative VUE and TUE differences were compared against boundaries of clinically relevant equivalent thresholds to assess their equivalency, using modified paired t-tests and Bayesian hierarchical modeling. Quantitatively, in tissues containing high concentrations of calcium or iodine, CT numbers measured in VUE images were significantly different from those in TUE images. CT numbers in VUE images were significantly lower than TUE images when calcium was present (e.g. in the spine, 73.1 HU lower, p < 0.0001); and significantly higher when iodine was present (e.g. in renal cortex, 12.9 HU higher, p < 0.0001). Qualitatively, VUE image ratings showed significantly inferior depiction of liver parenchyma compared to TUE images, and significantly more cortico-medullary differentiation in the kidney. Significant differences in VUE images compared to TUE images may limit their application and ability to replace TUE images in diagnostic abdominal CT imaging.
- 23 September 2020
- Published byĀ Public Library of Science (PLoS)Ā inĀ PLOS ONE
- Vol.Ā 15 Ā (9) , e0238582
Open AccessComparison of virtual to true unenhanced abdominal computed tomography images acquired using rapid kV-switching dual energy imaging
To compare āvirtualā unenhanced (VUE) computed tomography (CT) images, reconstructed from rapid kVp-switching dual-energy computed tomography (DECT), to ātrueā unenhanced CT images (TUE), in clinical abdominal imaging. The ability to replace TUE with VUE images would have many clinical and operational advantages. VUE and TUE images of 60 DECT datasets acquired for standard-of-care CT of pancreatic cancer were retrospectively reviewed and compared, both quantitatively and qualitatively. Comparisons included quantitative evaluation of CT numbers (Hounsfield Units, HU) measured in 8 different tissues, and 6 qualitative image characteristics relevant to abdominal imaging, rated by 3 experienced radiologists. The observed quantitative and qualitative VUE and TUE differences were compared against boundaries of clinically relevant equivalent thresholds to assess their equivalency, using modified paired t-tests and Bayesian hierarchical modeling. Quantitatively, in tissues containing high concentrations of calcium or iodine, CT numbers measured in VUE images were significantly different from those in TUE images. CT numbers in VUE images were significantly lower than TUE images when calcium was present (e.g. in the spine, 73.1 HU lower, p < 0.0001); and significantly higher when iodine was present (e.g. in renal cortex, 12.9 HU higher, p < 0.0001). Qualitatively, VUE image ratings showed significantly inferior depiction of liver parenchyma compared to TUE images, and significantly more cortico-medullary differentiation in the kidney. Significant differences in VUE images compared to TUE images may limit their application and ability to replace TUE images in diagnostic abdominal CT imaging.
- Open Access
A Time Series Graph Cut Image Segmentation Scheme for Liver Tumors
Tumor detection in biomedical imaging is a time-consuming process for medical professionals and is not without errors. Thus in recent decades, researchers have developed algorithmic techniques for image processing using a wide variety of mathematical methods, such as statistical modeling, variational techniques, and machine learning. In this paper, we propose a semi-automatic method for liver segmentation of 2D CT scans into three labels denoting healthy, vessel, or tumor tissue based on graph cuts. First, we create a feature vector for each pixel in a novel way that consists of the 59 intensity values in the time series data and propose a simplified perimeter cost term in the energy functional. We normalize the data and perimeter terms in the functional to expedite the graph cut without having to optimize the scaling parameter $\lambda$. In place of a training process, predetermined tissue means are computed based on sample regions identified by expert radiologists. The proposed method also has the advantage of being relatively simple to implement computationally. It was evaluated against the ground truth on a clinical CT dataset of 10 tumors and yielded segmentations with a mean Dice similarity coefficient (DSC) of .77 and mean volume overlap error (VOE) of 36.7%. The average processing time was 1.25 minutes per slice.Open AccessA Time Series Graph Cut Image Segmentation Scheme for Liver Tumors
Tumor detection in biomedical imaging is a time-consuming process for medical professionals and is not without errors. Thus in recent decades, researchers have developed algorithmic techniques for image processing using a wide variety of mathematical methods, such as statistical modeling, variational techniques, and machine learning. In this paper, we propose a semi-automatic method for liver segmentation of 2D CT scans into three labels denoting healthy, vessel, or tumor tissue based on graph cuts. First, we create a feature vector for each pixel in a novel way that consists of the 59 intensity values in the time series data and propose a simplified perimeter cost term in the energy functional. We normalize the data and perimeter terms in the functional to expedite the graph cut without having to optimize the scaling parameter $\lambda$. In place of a training process, predetermined tissue means are computed based on sample regions identified by expert radiologists. The proposed method also has the advantage of being relatively simple to implement computationally. It was evaluated against the ground truth on a clinical CT dataset of 10 tumors and yielded segmentations with a mean Dice similarity coefficient (DSC) of .77 and mean volume overlap error (VOE) of 36.7%. The average processing time was 1.25 minutes per slice. - Open Access
- 24 August 2018
- Published byĀ Springer NatureĀ inĀ Cancer Imaging
- Vol.Ā 18 Ā (1) , 30
Risk of renal events following intravenous iodinated contrast material administration among inpatients admitted with cancer a retrospective hospital claims analysis
There is little published evidence examining the use of contrast material (CM) and the risk of acute renal adverse events (AEs) in individuals with increasingly common risk factors including cancer and chronic kidney disease (CKD). The objective of this study was to use real world hospital data to test the hypothesis that inpatients with cancer having CT procedures with iodinated CM would have higher rates of acute renal AEs in comparison to inpatients without cancer. Inpatient hospital visits in the Premier Hospital Database from January 1, 2010 through September 30, 2015 were eligible for inclusion. The outcome of interest was a composite of acute renal AEs including: acute kidney injury, acute renal failure requiring dialysis, contrast induced-acute kidney injury and renal failure. Multivariable models, adjusted for differences in patient demographics and comorbid conditions, were used to estimate the incremental risk of acute renal AEs by CT (with or without iodinated CM), CKD stage and type of cancer. Among 29,850,475 inpatient visits across 611 hospitals, 7.4% had record of a CT scan, 5.9% had CKD, and 3.4% had the primary diagnosis of cancer. The baseline risk for an acute renal AE in patients without cancer or CKD and no CT or CM was 0.5%. The absolute risk increases from baseline by 0.2% with a CT and by 0.8% with iodinated CM. Patients with CKD having a CT scan with iodinated CM have an absolute risk of 4.1 to 9.7% depending on the stage of CKD. For patients with cancer, the absolute risk increases, varying from 0.3 to 2.3% depending on the type of cancer. Inpatients with cancer are at higher likelihood of developing acute renal AEs following CT with iodinated CM compared to those without a cancer. Understanding the underlying risks of acute renal AEs among complex inpatient admissions is an important consideration in treatment choices for oncology patients.
- 24 August 2018
- Published byĀ Springer NatureĀ inĀ Cancer Imaging
- Vol.Ā 18 Ā (1) , 30
Open AccessRisk of renal events following intravenous iodinated contrast material administration among inpatients admitted with cancer a retrospective hospital claims analysis
There is little published evidence examining the use of contrast material (CM) and the risk of acute renal adverse events (AEs) in individuals with increasingly common risk factors including cancer and chronic kidney disease (CKD). The objective of this study was to use real world hospital data to test the hypothesis that inpatients with cancer having CT procedures with iodinated CM would have higher rates of acute renal AEs in comparison to inpatients without cancer. Inpatient hospital visits in the Premier Hospital Database from January 1, 2010 through September 30, 2015 were eligible for inclusion. The outcome of interest was a composite of acute renal AEs including: acute kidney injury, acute renal failure requiring dialysis, contrast induced-acute kidney injury and renal failure. Multivariable models, adjusted for differences in patient demographics and comorbid conditions, were used to estimate the incremental risk of acute renal AEs by CT (with or without iodinated CM), CKD stage and type of cancer. Among 29,850,475 inpatient visits across 611 hospitals, 7.4% had record of a CT scan, 5.9% had CKD, and 3.4% had the primary diagnosis of cancer. The baseline risk for an acute renal AE in patients without cancer or CKD and no CT or CM was 0.5%. The absolute risk increases from baseline by 0.2% with a CT and by 0.8% with iodinated CM. Patients with CKD having a CT scan with iodinated CM have an absolute risk of 4.1 to 9.7% depending on the stage of CKD. For patients with cancer, the absolute risk increases, varying from 0.3 to 2.3% depending on the type of cancer. Inpatients with cancer are at higher likelihood of developing acute renal AEs following CT with iodinated CM compared to those without a cancer. Understanding the underlying risks of acute renal AEs among complex inpatient admissions is an important consideration in treatment choices for oncology patients.
- 1 August 2018
- Published byĀ American Roentgen Ray SocietyĀ inĀ American Journal of Roentgenology
- Vol.Ā 211 Ā (2) , W109-W115
Utility of Intermediate-Delay Washout CT Images for Differentiation of Malignant and Benign Adrenal Lesions: A Multivariate Analysis
OBJECTIVE. The objective of this study was to identify features that impact the diagnostic performance of intermediate-delay washout CT for distinguishing malignant from benign adrenal lesions. MATERIALS AND METHODS. This retrospective study evaluated 127 pathologically proven adrenal lesions (82 malignant, 45 benign) in 126 patients who had undergone portal venous phase and intermediate-delay washout CT (1ā3 minutes after portal venous phase) with or without unenhanced images. Unenhanced images were available for 103 lesions. Quantitatively, lesion CT attenuation on unenhanced (UA) and delayed (DL) images, absolute and relative percentage of enhancement washout (APEW and RPEW, respectively), descriptive CT features (lesion size, margin characteristics, heterogeneity or homogeneity, fat, calcification), patient demographics, and medical history were evaluated for association with lesion status using multiple logistic regression with stepwise model selection. Area under the ROC curve (Az) was calculated from both univariate and multivariate analyses. The predictive diagnostic performance of multivariate evaluations was ascertained through cross-validation. RESULTS. Az for DL, APEW, RPEW, and UA was 0.751, 0.795, 0.829, and 0.839, respectively. Multivariate analyses yielded the following significant CT quantitative features and associated Az when combined: RPEW and DL (Az = 0.861) when unenhanced images were not available and APEW and UA (Az = 0.889) when unenhanced images were available. Patient demographics and presence of a prior malignancy were additional significant factors, increasing Az to 0.903 and 0.927, respectively. The combined predictive classifier, without and with UA available, yielded 85.7% and 87.3% accuracies with cross-validation, respectively. CONCLUSION. When appropriately combined with other CT features, washout derived from intermediate-delay CT with or without additional clinical data has potential utility in differentiating malignant from benign adrenal lesions.
- 1 August 2018
- Published byĀ American Roentgen Ray SocietyĀ inĀ American Journal of Roentgenology
- Vol.Ā 211 Ā (2) , W109-W115
Utility of Intermediate-Delay Washout CT Images for Differentiation of Malignant and Benign Adrenal Lesions: A Multivariate Analysis
OBJECTIVE. The objective of this study was to identify features that impact the diagnostic performance of intermediate-delay washout CT for distinguishing malignant from benign adrenal lesions. MATERIALS AND METHODS. This retrospective study evaluated 127 pathologically proven adrenal lesions (82 malignant, 45 benign) in 126 patients who had undergone portal venous phase and intermediate-delay washout CT (1ā3 minutes after portal venous phase) with or without unenhanced images. Unenhanced images were available for 103 lesions. Quantitatively, lesion CT attenuation on unenhanced (UA) and delayed (DL) images, absolute and relative percentage of enhancement washout (APEW and RPEW, respectively), descriptive CT features (lesion size, margin characteristics, heterogeneity or homogeneity, fat, calcification), patient demographics, and medical history were evaluated for association with lesion status using multiple logistic regression with stepwise model selection. Area under the ROC curve (Az) was calculated from both univariate and multivariate analyses. The predictive diagnostic performance of multivariate evaluations was ascertained through cross-validation. RESULTS. Az for DL, APEW, RPEW, and UA was 0.751, 0.795, 0.829, and 0.839, respectively. Multivariate analyses yielded the following significant CT quantitative features and associated Az when combined: RPEW and DL (Az = 0.861) when unenhanced images were not available and APEW and UA (Az = 0.889) when unenhanced images were available. Patient demographics and presence of a prior malignancy were additional significant factors, increasing Az to 0.903 and 0.927, respectively. The combined predictive classifier, without and with UA available, yielded 85.7% and 87.3% accuracies with cross-validation, respectively. CONCLUSION. When appropriately combined with other CT features, washout derived from intermediate-delay CT with or without additional clinical data has potential utility in differentiating malignant from benign adrenal lesions.
- 1 July 2018
- Published byĀ ElsevierĀ inĀ Academic Radiology
- Vol.Ā 25 Ā (7) , 861-868
Combining Washout and Noncontrast Data From Adrenal Protocol CT
- 1 July 2018
- Published byĀ ElsevierĀ inĀ Academic Radiology
- Vol.Ā 25 Ā (7) , 861-868
Combining Washout and Noncontrast Data From Adrenal Protocol CT
- 1 April 2018
- Published byĀ American Roentgen Ray SocietyĀ inĀ American Journal of Roentgenology
- Vol.Ā 210 Ā (4) , W156-W163
Differentiation of Malignant and Benign Adrenal Lesions With Delayed CT: Multivariate Analysis and Predictive Models
OBJECTIVE. The purpose of this study is to identify imaging and patient parameters that affect the diagnostic performance of delayed contrast-enhanced CT for distinguishing malignant from benign adrenal lesions larger than 1 cm in adult patients and to derive predictive models. MATERIALS AND METHODS. This retrospective study assessed 97 pathologically proven adrenal lesions that had undergone unenhanced, portal venous, and 15-minute delayed CT. Quantitatively, single-parameter evaluations of lesion attenuation (in Hounsfield units) and absolute percentage enhancement washout (APEW) and relative percentage enhancement washout (RPEW) were performed. In addition, descriptive CT features (lesion size, margin definition, heterogeneity vs homogeneity, fat, and calcification) and patients' demographic characteristics and medical history of malignancy were evaluated for association with lesion status using multiple logistic regression with stepwise model selection. Areas under the ROC curve (Az) were determined for univariate and multivariate analyses. Leave-one-lesion-out cross-validation was applied to ascertain the predictive performance of single-parameter and multivariate evaluations. RESULTS. The Az values for unenhanced attenuation, portal venous attenuation, delayed attenuation, APEW, and RPEW were 0.835, 0.534, 0.847, 0.792, and 0.871, respectively. Multivariate analyses revealed that portal venous attenuation, delayed attenuation, and APEW were significant features, with an Az of 0.923 when combined. The addition of the descriptive CT features increased the Az to 0.938; patient age and a history of malignancy were additional significant factors, increasing the Az to 0.956 and 0.972, respectively. The combined predictive classifier yielded 89% accuracy under cross-validation, compared with the best commonly applied single-parameter evaluation (77% for RPEW < 40%). CONCLUSION. Multivariate imaging evaluation applied to delayed contrast-enhanced CT alone, with or without patient characteristics, improves diagnostic performance for characterizing adrenal lesions beyond those of single-parameter evaluations. Predictive formulas assessing the probabilities of lesion benignity or malignancy are provided.
- 1 April 2018
- Published byĀ American Roentgen Ray SocietyĀ inĀ American Journal of Roentgenology
- Vol.Ā 210 Ā (4) , W156-W163
Differentiation of Malignant and Benign Adrenal Lesions With Delayed CT: Multivariate Analysis and Predictive Models
OBJECTIVE. The purpose of this study is to identify imaging and patient parameters that affect the diagnostic performance of delayed contrast-enhanced CT for distinguishing malignant from benign adrenal lesions larger than 1 cm in adult patients and to derive predictive models. MATERIALS AND METHODS. This retrospective study assessed 97 pathologically proven adrenal lesions that had undergone unenhanced, portal venous, and 15-minute delayed CT. Quantitatively, single-parameter evaluations of lesion attenuation (in Hounsfield units) and absolute percentage enhancement washout (APEW) and relative percentage enhancement washout (RPEW) were performed. In addition, descriptive CT features (lesion size, margin definition, heterogeneity vs homogeneity, fat, and calcification) and patients' demographic characteristics and medical history of malignancy were evaluated for association with lesion status using multiple logistic regression with stepwise model selection. Areas under the ROC curve (Az) were determined for univariate and multivariate analyses. Leave-one-lesion-out cross-validation was applied to ascertain the predictive performance of single-parameter and multivariate evaluations. RESULTS. The Az values for unenhanced attenuation, portal venous attenuation, delayed attenuation, APEW, and RPEW were 0.835, 0.534, 0.847, 0.792, and 0.871, respectively. Multivariate analyses revealed that portal venous attenuation, delayed attenuation, and APEW were significant features, with an Az of 0.923 when combined. The addition of the descriptive CT features increased the Az to 0.938; patient age and a history of malignancy were additional significant factors, increasing the Az to 0.956 and 0.972, respectively. The combined predictive classifier yielded 89% accuracy under cross-validation, compared with the best commonly applied single-parameter evaluation (77% for RPEW < 40%). CONCLUSION. Multivariate imaging evaluation applied to delayed contrast-enhanced CT alone, with or without patient characteristics, improves diagnostic performance for characterizing adrenal lesions beyond those of single-parameter evaluations. Predictive formulas assessing the probabilities of lesion benignity or malignancy are provided.
- Open Access
- 7 February 2018
- Published byĀ Oxford University Press (OUP)Ā inĀ BJR|case reports
- Vol.Ā 4 Ā (3) , 20170104
Metastatic melanoma to the testis
This case report presents the ultrasound and positron emission tomography-computed tomography (PET-CT)imaging findings related to a patient with metastatic melanoma to the testis. We review this very rare entity and discuss the role of imaging. Differential considerations for a patient presenting with scrotal pain and swelling are quite wide, ranging from benign to malignant processes. The former include such entities as testicular torsion and epididymo-orchitis, and the latter, primary and secondary malignancies. Distinction between these entities is critically important because treatment pathways vary widely according to the precise diagnoses. Metastatic melanoma to the testicle has only been rarely reported and there have been very limited previous descriptions of its imaging findings. To the best of our knowledge, there have been no previous radiological reports describing both the ultrasound and PET-CT imaging findings in the same patient.
- 7 February 2018
- Published byĀ Oxford University Press (OUP)Ā inĀ BJR|case reports
- Vol.Ā 4 Ā (3) , 20170104
Open AccessMetastatic melanoma to the testis
This case report presents the ultrasound and positron emission tomography-computed tomography (PET-CT)imaging findings related to a patient with metastatic melanoma to the testis. We review this very rare entity and discuss the role of imaging. Differential considerations for a patient presenting with scrotal pain and swelling are quite wide, ranging from benign to malignant processes. The former include such entities as testicular torsion and epididymo-orchitis, and the latter, primary and secondary malignancies. Distinction between these entities is critically important because treatment pathways vary widely according to the precise diagnoses. Metastatic melanoma to the testicle has only been rarely reported and there have been very limited previous descriptions of its imaging findings. To the best of our knowledge, there have been no previous radiological reports describing both the ultrasound and PET-CT imaging findings in the same patient.